vs
Side-by-side financial comparison of Cintas (CTAS) and Zoetis (ZTS). Click either name above to swap in a different company.
Cintas is the larger business by last-quarter revenue ($2.8B vs $2.4B, roughly 1.2× Zoetis). Zoetis runs the higher net margin — 25.3% vs 17.7%, a 7.6% gap on every dollar of revenue. On growth, Cintas posted the faster year-over-year revenue change (9.3% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $425.0M). Over the past eight quarters, Cintas's revenue compounded faster (7.9% CAGR vs 4.4%).
Cintas Corporation is an American corporation headquartered in Mason, Ohio, which provides a range of products and services to businesses including uniforms, mats, mops, cleaning and restroom supplies, first aid and safety products, fire extinguishers and testing, and safety courses. Cintas is a publicly held company traded on the Nasdaq Global Select Market under the symbol CTAS and is a component of the S&P 500 Index.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
CTAS vs ZTS — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $2.4B |
| Net Profit | $495.3M | $603.0M |
| Gross Margin | 50.4% | 70.2% |
| Operating Margin | 23.4% | 31.9% |
| Net Margin | 17.7% | 25.3% |
| Revenue YoY | 9.3% | 3.0% |
| Net Profit YoY | 10.4% | 3.8% |
| EPS (diluted) | $1.21 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $2.4B | ||
| Q3 25 | $2.7B | $2.4B | ||
| Q2 25 | $2.7B | $2.5B | ||
| Q1 25 | $2.6B | $2.2B | ||
| Q4 24 | $2.6B | $2.3B | ||
| Q3 24 | $2.5B | $2.4B | ||
| Q2 24 | $2.5B | $2.4B | ||
| Q1 24 | $2.4B | $2.2B |
| Q4 25 | $495.3M | $603.0M | ||
| Q3 25 | $491.1M | $721.0M | ||
| Q2 25 | $448.3M | $718.0M | ||
| Q1 25 | $463.5M | $631.0M | ||
| Q4 24 | $448.5M | $581.0M | ||
| Q3 24 | $452.0M | $682.0M | ||
| Q2 24 | $414.3M | $624.0M | ||
| Q1 24 | $397.6M | $599.0M |
| Q4 25 | 50.4% | 70.2% | ||
| Q3 25 | 50.3% | 71.5% | ||
| Q2 25 | 49.7% | 73.6% | ||
| Q1 25 | 50.6% | 72.0% | ||
| Q4 24 | 49.8% | 69.5% | ||
| Q3 24 | 50.1% | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | 23.4% | 31.9% | ||
| Q3 25 | 22.7% | 37.0% | ||
| Q2 25 | 22.4% | 36.7% | ||
| Q1 25 | 23.4% | 36.5% | ||
| Q4 24 | 23.1% | 31.6% | ||
| Q3 24 | 22.4% | 36.6% | ||
| Q2 24 | 22.2% | 33.0% | ||
| Q1 24 | 21.6% | 34.1% |
| Q4 25 | 17.7% | 25.3% | ||
| Q3 25 | 18.1% | 30.0% | ||
| Q2 25 | 16.8% | 29.2% | ||
| Q1 25 | 17.8% | 28.4% | ||
| Q4 24 | 17.5% | 25.1% | ||
| Q3 24 | 18.1% | 28.6% | ||
| Q2 24 | 16.8% | 26.4% | ||
| Q1 24 | 16.5% | 27.4% |
| Q4 25 | $1.21 | $1.37 | ||
| Q3 25 | $1.20 | $1.63 | ||
| Q2 25 | $1.08 | $1.61 | ||
| Q1 25 | $1.13 | $1.41 | ||
| Q4 24 | $1.09 | $1.29 | ||
| Q3 24 | $1.10 | $1.50 | ||
| Q2 24 | $4.00 | $1.37 | ||
| Q1 24 | $3.84 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $200.8M | — |
| Total DebtLower is stronger | $2.4B | — |
| Stockholders' EquityBook value | $4.5B | $3.3B |
| Total Assets | $10.1B | $15.5B |
| Debt / EquityLower = less leverage | 0.54× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $200.8M | — | ||
| Q3 25 | $138.1M | $2.1B | ||
| Q2 25 | $264.0M | $1.4B | ||
| Q1 25 | $243.4M | $1.7B | ||
| Q4 24 | $122.4M | $2.0B | ||
| Q3 24 | $101.4M | $1.7B | ||
| Q2 24 | $342.0M | $1.6B | ||
| Q1 24 | $128.5M | $2.0B |
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $2.5B | — |
| Q4 25 | $4.5B | $3.3B | ||
| Q3 25 | $4.8B | $5.4B | ||
| Q2 25 | $4.7B | $5.0B | ||
| Q1 25 | $4.6B | $4.7B | ||
| Q4 24 | $4.3B | $4.8B | ||
| Q3 24 | $4.0B | $5.2B | ||
| Q2 24 | $4.3B | $5.0B | ||
| Q1 24 | $4.2B | $5.1B |
| Q4 25 | $10.1B | $15.5B | ||
| Q3 25 | $9.8B | $15.2B | ||
| Q2 25 | $9.8B | $14.5B | ||
| Q1 25 | $9.6B | $14.1B | ||
| Q4 24 | $9.4B | $14.2B | ||
| Q3 24 | $9.1B | $14.4B | ||
| Q2 24 | $9.2B | $14.2B | ||
| Q1 24 | $9.0B | $14.3B |
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.44× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 0.47× | — | ||
| Q1 24 | 0.58× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $531.2M | $893.0M |
| Free Cash FlowOCF − Capex | $425.0M | $732.0M |
| FCF MarginFCF / Revenue | 15.2% | 30.7% |
| Capex IntensityCapex / Revenue | 3.8% | 6.7% |
| Cash ConversionOCF / Net Profit | 1.07× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $1.8B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $531.2M | $893.0M | ||
| Q3 25 | $414.5M | $938.0M | ||
| Q2 25 | $635.7M | $486.0M | ||
| Q1 25 | $622.0M | $587.0M | ||
| Q4 24 | $441.4M | $905.0M | ||
| Q3 24 | $466.7M | $951.0M | ||
| Q2 24 | $693.0M | $502.0M | ||
| Q1 24 | $657.1M | $595.0M |
| Q4 25 | $425.0M | $732.0M | ||
| Q3 25 | $312.5M | $805.0M | ||
| Q2 25 | $521.1M | $308.0M | ||
| Q1 25 | $522.1M | $438.0M | ||
| Q4 24 | $340.0M | $689.0M | ||
| Q3 24 | $373.8M | $784.0M | ||
| Q2 24 | $591.1M | $370.0M | ||
| Q1 24 | $550.1M | $455.0M |
| Q4 25 | 15.2% | 30.7% | ||
| Q3 25 | 11.5% | 33.5% | ||
| Q2 25 | 19.5% | 12.5% | ||
| Q1 25 | 20.0% | 19.7% | ||
| Q4 24 | 13.3% | 29.7% | ||
| Q3 24 | 14.9% | 32.8% | ||
| Q2 24 | 23.9% | 15.7% | ||
| Q1 24 | 22.9% | 20.8% |
| Q4 25 | 3.8% | 6.7% | ||
| Q3 25 | 3.8% | 5.5% | ||
| Q2 25 | 4.3% | 7.2% | ||
| Q1 25 | 3.8% | 6.7% | ||
| Q4 24 | 4.0% | 9.3% | ||
| Q3 24 | 3.7% | 7.0% | ||
| Q2 24 | 4.1% | 5.6% | ||
| Q1 24 | 4.4% | 6.4% |
| Q4 25 | 1.07× | 1.48× | ||
| Q3 25 | 0.84× | 1.30× | ||
| Q2 25 | 1.42× | 0.68× | ||
| Q1 25 | 1.34× | 0.93× | ||
| Q4 24 | 0.98× | 1.56× | ||
| Q3 24 | 1.03× | 1.39× | ||
| Q2 24 | 1.67× | 0.80× | ||
| Q1 24 | 1.65× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTAS
| Uniform Rental And Facility Services Segment | $2.2B | 77% |
| First Aid And Safety Services Segment | $342.2M | 12% |
| Fire Protection Services | $222.5M | 8% |
| Uniform Direct Sales | $79.8M | 3% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
